LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Inicio・Lista de Acciones・Erasca Inc

Erasca Inc

Cerrado

10.38 2.77

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.06

Máximo

10.67

Métricas clave
By Trading Economics
Ingresos	1.5M -29M
Empleados	103
EBITDA	-2M -32M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+99.6% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.7B 3.2B
Apertura anterior	7.61
Cierre anterior	10.38

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

1.39 / 1.44 Soporte y Resistencia

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 may 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 may 2026, 23:46 UTC

Charlas de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 may 2026, 23:33 UTC

Charlas de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 may 2026, 22:37 UTC

Charlas de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 may 2026, 22:32 UTC

Ganancias

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 may 2026, 22:02 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 may 2026, 21:49 UTC

Ganancias

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 may 2026, 21:42 UTC

Charlas de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 may 2026, 21:23 UTC

Adquisiciones, fusiones, absorciones

CSG Systems Sale to NEC Gets CFIUS Clearance

11 may 2026, 21:12 UTC

Ganancias

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 may 2026, 21:12 UTC

Ganancias

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 may 2026, 20:44 UTC

Ganancias

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 may 2026, 20:43 UTC

Ganancias

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Rev $136.4M >CLSK

11 may 2026, 20:30 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Cont Ops EPS $2.24 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Rev $1.6B >STE

11 may 2026, 20:30 UTC

Ganancias

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Adj EPS $2.83 >STE

11 may 2026, 20:22 UTC

Acciones populares

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 may 2026, 19:37 UTC

Ganancias

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 may 2026, 19:32 UTC

Charlas de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

99.6% repunte

Estimación a 12 Meses

Media 20.2 USD 99.6%

Máximo 30 USD

Mínimo 9 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Erasca Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.